What's Hot
View all perspectives
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded patients with history of cancer.
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Janet Pope Janetbirdope
2 years 5 months ago
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185
Janet Pope Janetbirdope
2 years 5 months ago
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
Janet Pope Janetbirdope
2 years 5 months ago
Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i
Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal.
David Liew drdavidliew
2 years 5 months ago
ARIAA: saw 18m results #EULAR2022
(alluded to at #ACR21)
High-risk ACPA+ clinically suspect arthralgias
Didn't progress to arthritis:
after 6m abatacept: 92% vs 65%
12m after abatacept stopped: 65% vs 43%
(tighter at points)
How to pick those that benefit?
POS0531 @RheumNow https://t.co/dkf1jU5gx7
Dr. Antoni Chan synovialjoints
2 years 5 months ago
As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA). Here are my top picks from this year's meeting.
Dr. John Cush RheumNow
2 years 5 months ago
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
https://t.co/ExCXY6Xbl4
@Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI
Poster Hall